Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07161011 · ClinicalTrials.gov registry record · Phase 2
Phase 2b Controlled Study of Dosing Techniques - Part B
A Phase 2 study of Dry Eye, sponsored by IVIEW Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT07161011: Active Phase 2 study of Dry Eye, sponsored by IVIEW Therapeutics.
NCT07161011 is a Phase 2 study of Dry Eye that is active but no longer recruiting, run by IVIEW Therapeutics. The registered enrollment target is 30 participants, below the 95-participant average among 41 other Dry Eye trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07161011, a Phase 2 study of Dry Eye, is active but no longer recruiting, sponsored by IVIEW Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Double-masked, dose-response of two concentrations of IVW-1001
Primary Outcome
Tear production
Conditions Studied
Interventions
- DRUG IVW-1001 Ophthalmic Eyelid Wipe 0.2%
- DRUG IVW-1001 Ophthalmic Eyelid Wipe 0.4%
Study Locations (1)
California
- Eye Research Foundation - Newport Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-09-08 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 2 |
What the registry record for NCT07161011 still lists
NCT07161011 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 95-participant average among 41 other Dry Eye trials with a reported enrollment target (68% lower).
The record links to 1 condition, with Dry Eye appearing as the primary indexed condition, and to 2 interventions - of which IVW-1001 Ophthalmic Eyelid Wipe 0.2% is the first listed.
NCT07161011 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT07161011 about?
NCT07161011 is a clinical study titled "Phase 2b Controlled Study of Dosing Techniques - Part B". Double-masked, dose-response of two concentrations of IVW-1001
What is the current status of trial NCT07161011?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2025-09-08. Estimated completion is 2025-12-31.
What conditions does trial NCT07161011 study?
This clinical trial studies the following conditions: Dry Eye.
What interventions are being tested in trial NCT07161011?
The interventions under investigation include: IVW-1001 Ophthalmic Eyelid Wipe 0.2% (DRUG), IVW-1001 Ophthalmic Eyelid Wipe 0.4% (DRUG).
Who is sponsoring clinical trial NCT07161011?
This trial is sponsored by IVIEW Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07161011 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07161011's enrollment target sits among peer trials
30 31st of 41 higher than 9 of 41 other Dry Eye trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dry Eye trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye
RECRUITING · Phase 2
-
An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye
RECRUITING · Phase 2
-
A Study to Assess the Safety and Efficacy of ECF843 vs Vehicle in Subjects With Dry Eye Disease
COMPLETED · Phase 2
-
An 8-week Study to Evaluate Safety and Efficacy of NGF Eye Drops Solution Versus Vehicle in Patients With Dry Eye
COMPLETED · Phase 2
-
Can Pregabalin Reduce the Frequency and Severity of Dry Eye Symptoms After Laser-assisted in Situ Keratomileusis?
COMPLETED · Phase 2
-
Treatment of Patients With Blepharitis and Facial Rosacea
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI